Evaluation of two type of quadruple regimens of Helicobacter Pylori

Evaluation of based_furazolidone quadruple regimens in comparision with based_claritromycine for eradication of Helicobacter pylori

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171203037734N1

Enrollment

194

Registered

2018-06-10

Start date

2018-11-01

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H pylori eradication. Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere

Interventions

Intervention 1: Intervention group: ( n=97 ) will receive furazolidone_based quadruple therapy (furazolidone 100 mg BD, Bismuth subcitrate 240 mg BD, Pantoprazole 40 mg BD, Amoxicilline 1000mg BD ).

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with peptic ulcer, dyspepsia, Gastritis with confirmation H pylori Age more than 18

Exclusion criteria

Exclusion criteria: Age lesser than 18

Design outcomes

Primary

Measure	Time frame
Rate of H pylori eradication. Timepoint: Four weeks after treatment. Method of measurement: Urea breath test(UBT).	—

Secondary

Measure	Time frame
Side effect. Timepoint: Four weeks after treatment. Method of measurement: Patient's comments and examination by physician.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPejman Alavinejad

Ahvaz University of Medical Sciences

pezhmanalavinejad@gmail.com+98 61 3374 3013

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026